GlassScriptPhysician profile
Anh P Dang-Vu
NPI 1114025178
$9,963.05
in general payments reported to CMS, 2019-2025
34 companies · $947 in 2025
The $947 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,604 · 2020: $1,035 · 2021: $1,638 · 2022: $1,563 · 2023: $1,664 · 2024: $1,512 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,919 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,918.73 |
| Education | $204.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,071.56 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $862.19 | 2019-2025 | |
| Janssen Biotech, INC. | $847.38 | 2019-2025 | Tremfya, Stelara, Simponi |
| Incyte Corporation | $811.20 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $717.07 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Arcutis Biotherapeutics, INC. | $576.57 | 2023-2025 | Zoryve |
| Ucb, INC. | $399.82 | 2019-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $361.14 | 2019-2025 | Aklief, Nemluvio, Oracea |
| E.R. Squibb & Sons, L.L.C. | $343.08 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $334.71 | 2019-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $306.42 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $264.37 | 2019-2025 | Blu-U, Odomzo |
| Genzyme Corporation | $248.60 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $241.53 | 2019-2024 | |
| Lilly USA, LLC | $210.78 | 2019-2024 | Taltz, Olumiant, Zepbound |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $203.45 | 2019-2022 | |
| Dermavant Sciences, INC. | $144.06 | 2023-2024 | Vtama |
| Epi Health, LLC | $140.33 | 2019-2022 | |
| Biofrontera INC. | $129.64 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Sanofi-Aventis U.S. LLC | $119.38 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $109.55 | 2020-2021 | |
| Almirall LLC | $86.44 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $75.00 | 2019 | |
| Journey Medical Corporation | $74.71 | 2019-2022 | |
| Organon LLC | $67.71 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.14 | 2022-2023 | Spevigo |
| Organogenesis INC. | $35.21 | 2024 | |
| Amgen INC. | $29.88 | 2023 | Otezla, Enbrel |
| Paratek Pharmaceuticals, INC. | $23.39 | 2025 | Nuzyra |
| Glenmark Therapeutics INC. | $17.00 | 2019 | |
| Aclaris Therapeutics, INC. | $16.58 | 2019 | |
| Mission Pharmacal Company | $16.56 | 2020 | |
| Taro Pharmaceuticals USA, INC. | $15.40 | 2019 | |
| Botanix Sb INC | $14.20 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anh Dang-Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.